Concurrent antiretroviral therapy required, except for patients who have exhausted all available treatment options

Must be on a stable dose for ≥ 4 weeks

PATIENT CHARACTERISTICS:

Life expectancy ≥ 3 months

No other neoplasia requiring cytotoxic therapy

Not pregnant or nursing

Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment

PRIOR CONCURRENT THERAPY:

See Disease Characteristics

No prior anthracycline therapy

At least 4 weeks since prior antineoplastic treatment for KS, including any of the following:

Chemotherapy (6 weeks for nitrosoureas or mitomycin C)

Radiotherapy

Local therapy

Biological therapy

Investigational therapy

At least 60 days since prior local therapy of any KS indicator lesion unless lesion has clearly progressed since treatment

No other concurrent investigational drugs, cytotoxic chemotherapy, or KS-specific treatment

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00427414